Mainz Biomed presents results of ColoFuture study

Mainz Biomed is presenting its groundbreaking results of its ColoFuture Study. Originally scheduled for presentation by Dr Moritz Eidens, the Company’s Chief Scientific Officer, to assembled academics as part of a poster session at the 4th International Conference on Gastroenterology in Paris, the event has since been rescheduled from October to December. In consultation with the Conference leadership, Mainz Biomed has opted to release the eagerly anticipated ColoFuture results in line with the original conference schedule. The ColoFuture study was a multi-center international clinical trial assessing the potential to integrate a portfolio of novel gene expression biomarkers into ColoAlert, the Company’s highly efficacious, and easy-to-use screening test for colorectal cancer which is being commercialized across Europe and in select international territories. The presented results of the groundbreaking study included a sensitivity for CRC of 94% with a specificity of 97% and a sensitivity for advanced adenoma of 80%.